32 Participants Needed

Azer-cel for Autoimmune Disease

Recruiting at 1 trial location
TT
Overseen ByTG Therapeutics Clinical Support Team
Age: 18 - 65
Sex: Any
Trial Phase: Phase 1
Sponsor: TG Therapeutics, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).

Will I have to stop taking my current medications?

Yes, you will need to stop taking your current disease modifying therapy (DMT) before joining the trial, and there is a specific washout period (time without taking certain medications) required before receiving treatment.

Are You a Good Fit for This Trial?

This trial is for individuals with progressive forms of Multiple Sclerosis, including Primary Progressive and Secondary Progressive MS. Participants must have stopped any disease modifying therapy before joining the study and meet specific criteria for medication washout.

Inclusion Criteria

My condition is Progressive Multiple Sclerosis.
I have stopped all disease modifying treatments as required.

Exclusion Criteria

Viral Screening: Evidence of chronic active or history of hepatitis B virus (HBV), Seropositive for human immunodeficiency virus (HIV) antibody
I have not had treatments like CAR T-cell therapy.
I have had cancer that was not in remission for at least 2 years.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a single dose of intravenous (IV) infusion of azer-cel at different dose levels

4 weeks
1 visit (in-person) on Day 0

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Azercabtagene zapreleucel (azer-cel)
Trial Overview The trial is testing Azercabtagene zapreleucel (azer-cel) to find out the safest and most effective dose for treating B-cell mediated autoimmune disorders, specifically focusing on its use in Multiple Sclerosis.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Azer-celExperimental Treatment1 Intervention
Participants will receive single dose of intravenous (IV) infusion of azer-cel at different dose levels, on Day 0 of the treatment period.

Find a Clinic Near You

Who Is Running the Clinical Trial?

TG Therapeutics, Inc.

Lead Sponsor

Trials
41
Recruited
6,900+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security